脂蛋白相关磷脂酶 A2作为心血管疾病的炎性标志物,在动脉粥样硬化发病、进展和斑块破裂中起关键作用.近年来对脂蛋白相关磷脂酶的研究逐渐增多,与心血管疾病的相关性已得到大量实验及病理研究证实,但目前对心血管疾病的风险预测仍存在部分争议,如急性心肌梗死后,脂蛋白相关磷脂酶A2水平能否更好地预测心血管事件的发生.同时脂代谢治疗是否通过降低脂蛋白相关磷脂酶活性转化为较低的病死率和心血管事件发生率仍未研究清楚.脂蛋白相关磷脂酶 A2的特异性抑制剂——Darapladib的两项三期临床试验结果已经完成.现就脂蛋白相关磷脂酶A2在心血管疾病中的价值、争议等方面做一综述.“,”Lipoprotein-associated phospholipase A2(LP-PLA2)plays a significant role in the pathogenesis and deterioration of ather-osclerosis.Recently,with increasing studies of Lp-PLA2,many experimental and pathological investigations have validated its correlation with cardiovascular diseases.However,the risk profile of cardiovascular diseases remains controversial.For example,whether the level of Lp-PLA2 can effectively predict the occurrence of cardiovascular events after myocardial infarction is still under debate.In addition,it is ambiguous that whether lipid metabolism therapy can lower mortality rates and the incidence of cardiovascular events through inactivating Lp -PLA2.Lp-PLA2 specific inhibitor—Darapladib two phase Ⅲclinical trial results have been completed.In this paper we will further discuss about the value and the arguments of Lp-PLA2 in the study of cardiovascular diseases.